Changes in gene explain more of inherited risk for rare disease
- Created on March 03, 2014
The formation of multiple schwannomas is one sign that a person has the genetic disorder called schwannomatosis, which is one of the three major forms of neurofibromatosis, besides neurofibromatosis types 1 and 2. The condition is so named because the tumors originate in Schwann cells that form a nerve sheath and insulate nerve pathways to cause severe, chronic pain in many patients.
To date, physicians cannot give most patients a confirmed diagnosis for schwannomatosis, even if they show symptoms, because changes in genes linked to the condition by past studies explain only about 50 percent of familial and less than 10 percent of sporadic cases.
Work in 2007 determined that inheritable mutations in SMARCB1 predisposed to schwannomatosis. In addition, the schwannomas showed a loss of the long arm of chromosome 22, and different mutations in the neurofibromatosis type 2 (NF2) gene were found in each tumor studied.
Despite these many known details, much of the risk for schwannomatosis remained unexplained going into the current study. Several research groups had proposed that other schwannomatosis-predisposing genes existed, but no one had found any.
Specializing in genetic studies for all forms of the neurofibromatoses, the UAB Medical Genomics Laboratory chose to focus its research on a subset of schwannomatosis samples that did not harbor SMARCB1 mutations, which framed their experiments such that the role of LZTR1 was revealed.
“We have been working urgently to identify the genetic mechanisms behind these diseases because doing so is central to efforts to understand schwannoma tumor development as well as to identify new drug treatments,” said Ludwine Messiaen, Ph.D., director of the Medical Genomics Laboratory, professor in the Division of Clinical Genetics in the Department of Genetics within the UAB School of Medicine and corresponding study author. “This is pertinent as only some of the schwannomas can be surgically removed without neurological consequences, and there is no widely accepted approach for treating the severe, chronic pain in these patients.”
The study, conceived and coordinated by Arkadiusz Piotrowski of the University of Gdansk in Poland and Messiaen, resulted in the identification of LZTR1 on chromosome 22q as a novel tumor-suppressor gene predisposing to multiple schwannomas in patients without a mutation in SMARCB1. The results were seen in patients whose schwannomas also showed a loss of the long arm of chromosome 22 and a different somatic NF2 mutation in each tumor.
The team found that in all 25 schwannomas studied from 16 unrelated schwannomatosis patients, all tumors showing a loss of the long arm of chromosome 22 and a different somatic NF2 mutation in each tumor also had LZTR1 mutations present, strongly supporting the contribution to the disease by the combination of these factors.
The LZTR1 mutations were found using massive parallel sequencing (e.g. “next-generation sequencing”) of highly evolutionary conserved sequences specifically on chromosome 22. LZTR1 mutations likely will be found in a high fraction of familial as well as sporadic schwannomatosis patients, whose predisposition is not caused by SMARCB1, says Messiaen. Indeed, LZTR1 mutations were found in 6/6 familial and 8/11 sporadic such patients.
Both causal genes, LZTR1 and SMARCB1, show a potential functional link to chromatin remodeling mechanisms, which play a crucial role in cell differentiation and adaptation to environmental stimuli. Further, LZTR1 and SMARCB1 are known to interact with histone deacetylase 4 or HDAC4, which is a target for histone deacetylase inhibitors, a new class of anti-tumor drugs. The present findings will encourage further studies aiming at potential treatment for schwannomatosis.
The results published today will have broader implications, as LZTR1 was recently shown, in an independent study, to contribute to tumor development in a subset of patients with glioblastoma multiforme, the most aggressive type of brain tumor.
“Recent independent studies have shown that SMARCB1 and LZTR1 interact with histone deacetylase 4, and histone deacetylase inhibitors are emerging as a new class of anti-tumor drugs,” said Bruce Korf, M.D., Ph.D., chair of the UAB Department of Genetics, a study co-author and principal investigator for The Neurofibromatosis Clinical Trials Consortium at UAB. “One of these drugs, called AR-42, was recently reported to inhibit growth in schwannoma and meningioma cells. This creates the prospect of further testing of the drug as a potential treatment for schwannomatosis.”
Along with Messiaen and Piotrowski, study authors within the UAB Medical Genomics Laboratory were Jing Xie, Ying F. Liu, Alicia Gomes and Chuanhua Fu. Also making important contributions were Piotr Madanecki with the Medical University of Gdansk in Poland; Michael R. Crowley, David K. Crossman and Bruce Korf of the Heflin Center for Genomic Sciences at UAB; Linlea Armstrong in the Department of Medical Genetics at University of British Columbia in Vancouver; Dusica Babovic-Vuksanovic in the Department of Medical Genetics at the Mayo Clinic College of Medicine in Rochester; Amanda Bergner and Jaishri Blakeley from the Johns Hopkins Comprehensive Neurofibromatosis Center; Andrea Blumenthal and Stephanie Hurst of the Lakeridge Health Corporation, Oshawa, Ontario, Canada; Molly Daniels and John Slopis at the MD Anderson Cancer Center in Houston; Howard Feit in the Department of Neurology at Henry Ford Hospital in Detroit; Kathy Gardner in the Department of Neurology at Veterans Affairs Hospital of Pittsburgh; Christine Kobelka and Pim Suwannarat from Kaiser Permanente Genetics in San Francisco; Chung Lee, Katherine Rauen and Andrea Zanko in the Division of Medical Genetics at the University of California at San Francisco; and Rebecca Nagy and Judith Westman in the Division of Human Genetics at Ohio State University.
The research was supported by the Children’s Tumor Foundation, including a CTF Young Investigator Award to Piotrowski, and by internal funding from the UAB Medical Genomics Laboratory.
9th Annual Genetics Scientific Retreat
- Created on August 26, 2013
The 9th Annual Scientific Retreat
Hosted by UAB, Department of Genetics in conjunction with HudsonAlpha Institute for Biotechnology
Friday, November 7, 2014
HudsonAlpha Institute for Biotechnology
Keynote Presentation by
Mary V. Relling , PharmD
Chair, Department of Pharmaceutical Sciences
St. Jude Children’s Research Hospital
UAB and Birmingham Jewish Federation and Foundation offer genetic screening
- Created on January 07, 2013
One in four Jewish individuals of Central and Eastern European descent is a carrier for at least one of 19 preventable genetic disorders, many of which strike in childhood, have no cure and can lead to an early death.
On Jan. 13, 2013, the Levite Jewish Community Center, 3960 Montclair Road in Birmingham, will hold a community-wide screening from 11:00.a.m. to 4:00 p.m. for potential carriers of these genetic disorders.
The Birmingham Jewish Federation and Foundation host this screening in partnership with the National Victor Center for the Prevention of Jewish Genetic Diseases at Einstein Medical Center in Philadelphia and UAB’s Department of Genetics. Lane Rutledge, M.D., professor in Genetics, and Katie Nelson, a genetics counselor, will provide genetic counseling.
CME: Genetics and Genomics in Medical Practice
- Created on July 10, 2013
Genetics and Genomics in Medical Practice
Learn how genetics and genomics can be used in medical practice. Topics include newborn screening, perinatal diagnosis, pharmacogenetics, predictive testing, and new advances in genetic diagnosis across the lifespan, including whole genome sequencing.
Up to 6.5 AMA PRA Category 1 CreditsTM available
Up to 6.5 Category 2 CEU Credits also available to genetic counselors
Friday, August 23, 2013
8:00 a.m. – 5:00 p.m.
UAB Alumni House
1301 10th Avenue South
Birmingham, AL 35294
The University of Alabama School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Alabama School of Medicine designates this live activity for a maximum of 6.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The boards of nursing in many states, including Alabama, recognize Category 1 continuing medical education courses as acceptable activities for the renewal of license to practice nursing.
This course is eligible for Category 2 CEU credits for genetic counselors.
Sponsored by UAB Department of Genetics, the UAB Center for Clinical and Translational Science and the University of Alabama School of Medicine Division of Continuing Medical Education.
The University of Alabama at Birmingham is an equal opportunity/affirmative action institution.
Click here for agenda
Register online at www.uab.edu/medicine/geneticsCME
For more information, call 205-934-7299 or email questions to email@example.com.
Registration Fee: $100 before August 1, 2013; $125 after July 31, 2013.